Critical Review: Flamel Technologies (AVDL) & Acura Pharmaceuticals (NASDAQ:ACUR)

Acura Pharmaceuticals (NASDAQ: ACUR) and Flamel Technologies (NASDAQ:AVDL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitabiliy.

Valuation & Earnings

This table compares Acura Pharmaceuticals and Flamel Technologies’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Acura Pharmaceuticals $6.96 million N/A -$2.50 million ($0.83) -0.66
Flamel Technologies $151.93 million 2.95 $60.49 million ($0.32) -33.87

Flamel Technologies has higher revenue and earnings than Acura Pharmaceuticals. Flamel Technologies is trading at a lower price-to-earnings ratio than Acura Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Acura Pharmaceuticals has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. Comparatively, Flamel Technologies has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.


This table compares Acura Pharmaceuticals and Flamel Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acura Pharmaceuticals 14.91% 112.19% 19.04%
Flamel Technologies -7.28% 14.49% 2.74%

Analyst Ratings

This is a breakdown of recent ratings for Acura Pharmaceuticals and Flamel Technologies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acura Pharmaceuticals 0 0 2 0 3.00
Flamel Technologies 0 0 2 0 3.00

Acura Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 1,355.07%. Flamel Technologies has a consensus target price of $16.00, indicating a potential upside of 47.60%. Given Acura Pharmaceuticals’ higher probable upside, research analysts clearly believe Acura Pharmaceuticals is more favorable than Flamel Technologies.

Institutional & Insider Ownership

31.2% of Acura Pharmaceuticals shares are held by institutional investors. Comparatively, 70.5% of Flamel Technologies shares are held by institutional investors. 7.4% of Acura Pharmaceuticals shares are held by insiders. Comparatively, 5.1% of Flamel Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


Acura Pharmaceuticals beats Flamel Technologies on 6 of the 10 factors compared between the two stocks.

Acura Pharmaceuticals Company Profile

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Flamel Technologies Company Profile

Flamel Technologies S.A. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms. The Company owns and develops drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company has two direct operating subsidiaries: Flamel US Holdings, Inc. and Flamel Irish Holdings, Ltd.

This story was originally published by WKRB News ( and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.


Leave a Reply

© 2006-2017 WKRB News.